# Ipamorelin: the other door on the same cell

> Ipamorelin at GHS-R1a — Growth Hormone Axis research peptides — Ipamorelin mapped precisely: a selective ghrelin-receptor (GHS-R1a) agonist, its measured two-hour half-life and single discrete GH pulse, its failed Phase 2 endpoint, and the class-level cardiac signal. Growth Hormone Axis research peptides, cited and dose-free.

**02 / ghrelin-receptor agonist**

A five-residue peptide that releases growth hormone through GHS-R1a rather than GHRHR — selective enough to leave cortisol and prolactin alone, and short enough that its whole effect is one pulse.

## Start here

Ghrelin is the hormone the stomach releases when it is empty. Most people know it as the hunger signal, but it has a second job: it tells the pituitary to release growth hormone, and it does so through its own receptor, one that has nothing to do with the receptor the brain's own growth-hormone signal uses.

Ipamorelin is a five-building-block synthetic peptide that switches on that ghrelin receptor. The result is a burst of growth hormone that rises and falls quickly — in measurements taken in healthy volunteers, the response peaked around forty minutes and the peptide's own half-life was about two hours [11].

Its selling point among the older drugs in its family is what it does not do. Earlier compounds of this type also pushed up stress hormones like cortisol, and prolactin. Ipamorelin, in the work that first characterised it, did not. That is a narrower, cleaner signal — not a stronger or a safer one, and the difference matters when reading claims about it.

## What it is

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2. Alpha-aminoisobutyric acid sits at position 1, and D-2-naphthylalanine and D-phenylalanine confer resistance to proteases. It was derived from GHRP-1 by removing the central Ala-Trp dipeptide, and it is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor, GHS-R1a.

It has never been approved as a drug anywhere. It was investigated for postoperative ileus and did not proceed [10]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list following nominator withdrawal, and both the acetate and the free base were reviewed at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. What circulates now is research-grade material sold for laboratory use, outside pharmaceutical quality assurance.

That regulatory trajectory is worth reading carefully, because it runs opposite to sermorelin's. The absence of approval here does not reflect a development programme that was never finished. It reflects one that finished and missed.

## How it works

Ipamorelin binds GHS-R1a on pituitary somatotrophs and triggers a pulse of growth-hormone release. The receptor is not GHRHR, the intracellular route is not the Gs/cAMP/PKA cascade that GHRH analogs use, and the release mechanism is distinct from — and complementary to — the GHRH mechanism. That complementarity is the entire pharmacological basis for combining a ghrelin-receptor agonist with a GHRH analog such as CJC-1295, and it is a statement about receptors, not about outcomes.

The compound's signature is selectivity. Unlike the earlier growth-hormone-releasing peptides GHRP-6 and GHRP-2, ipamorelin releases GH without meaningfully raising ACTH, cortisol or prolactin, even well above the exposure that produces half its maximal GH effect. Removing adrenocortical stimulation and hyperprolactinaemia from the profile is a real and specific advantage over its predecessors. It is not a claim that the compound has no off-target activity.

GHS-R1a is not expressed only on somatotrophs, and the receptor's other locations are where the rest of ipamorelin's biology lives: enteric and vagal neurons involved in gastric motility, pancreatic islet cells where a growth-hormone-independent insulin-releasing action has been shown ex vivo, and hypothalamic appetite circuitry, which is the source of the class-level orexigenic effect. A selective GH secretagogue at the pituitary is still a ghrelin-receptor agonist everywhere else.

The kinetics are the other half of the mechanism. Population pharmacokinetic-pharmacodynamic modelling in healthy male volunteers, eight per dose level receiving five 15-minute intravenous infusions of 4.21 to 140.45 nanomoles per kilogram, found dose-proportional kinetics with a terminal half-life of approximately 2 hours, clearance of 0.078 litres per hour per kilogram and a steady-state volume of distribution of 0.22 litres per kilogram; the growth-hormone response peaked at about 0.67 hours — roughly 40 minutes — as a single discrete pulse [11]. Compared with the multi-day residence of CJC-1295 with DAC [4], this is a different pharmacological object entirely.

## What the research shows

**The one controlled human trial missed.** The only published Phase 2 randomised controlled trial of ipamorelin enrolled 114 adults undergoing bowel resection, given 0.03 mg/kg intravenously twice daily for up to seven days. It did not meet its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin against 32.6 hours with placebo, p = 0.15. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm [10]. A near-eight-hour numerical difference that does not reach significance in 114 patients is exactly the result that generates enthusiastic secondary summaries; the trial's own conclusion is that the endpoint was not met.

**Human pharmacology is characterised; human outcomes are not.** The PK/PD study described above [11] remains the reference description of what ipamorelin does to GH in people: dose-proportional, short, one pulse. Beyond those two studies there is no human dataset — no Phase 3, no long-term safety database, and no published pharmacokinetics for the subcutaneous route that dominates off-label use.

**Animal work is where the effect sizes live.** Subcutaneous ipamorelin at 18, 90 and 450 micrograms per day, divided three times daily for 15 days, dose-dependently increased the longitudinal bone growth rate of adult female Sprague-Dawley rats from 42 micrometres per day on vehicle to 44, 50 and 52 micrometres per day respectively — with no change in total IGF-1, IGF-binding proteins or bone turnover markers [12]. A growth effect without an IGF-1 change is a genuinely interesting mechanistic result and a poor foundation for a body-composition claim in humans.

**The most recent in-vivo study is modest.** In a 2024 ferret study, intraperitoneal ipamorelin at 1 to 3 mg/kg inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase, 48 to 72 hours in, but had no anti-emetic effect on either acute or delayed emesis — in contrast to intracerebroventricular anamorelin, which reduced acute emesis by 60% [8].

**A class-level cardiac signal sits behind all of it.** An integrated preclinical safety-pharmacology study of a different GHS-R1a agonist, GSK894281, found dose-dependent myocardial degeneration and necrosis in rats after 28 days of oral dosing, visible on histopathology and electron microscopy and accompanied by elevated serum heart-type fatty-acid-binding protein at the highest doses, while serum cardiac troponin was not elevated [9]. Ipamorelin was not the tested compound and no equivalent long-duration cardiovascular study of ipamorelin exists in any species. The relevance is that chronic systemic agonism at this receptor class has produced cardiac lesions in an animal model, and that the conventional cardiac biomarker did not flag them.

## Reported effects, cautions and safety

This paragraph is anecdotal, not clinical evidence — community reports from research-use forums, uncontrolled, unverified as to material or exposure, and recorded here without any quantities. Deeper, more restorative sleep is the most consistently cited benefit, often with vivid dreams in the first week or two that settle afterwards. Faster physical recovery and reduced post-training soreness are frequently described; a gradual shift toward a leaner appearance over weeks to months is reported occasionally and is heavily confounded by concurrent diet and training. On the adverse side, a transient facial flush or head-rush within roughly a quarter of an hour of administration is widely noted and often misread in forums as proof of activity; tingling in the extremities, mild puffiness, increased hunger in the hours afterwards, early lightheadedness, injection-site irritation, and a fading of perceived effect after several months of uninterrupted use are all reported occasionally. Every item in that list is a self-report.

The documented cautions come from mechanism and from the published record:

- **Proliferative disease.** GH stimulates hepatic IGF-1, and IGF-1 is a well-characterised mitogen. The concern that sustained increases in GH pulse amplitude could accelerate proliferative activity in pre-existing or occult tumours is mechanistic and class-level. No ipamorelin-specific carcinogenicity or tumour-promotion study exists in humans.
- **Glucose regulation is unpredictable here, not merely impaired.** GH is counter-regulatory and reduces peripheral insulin sensitivity. Ipamorelin additionally has a GH-independent insulinotropic action: ex vivo pancreatic tissue from both normal and diabetic rats released insulin directly in response to it. Two opposing influences on glycaemia, with no human glycaemic data at research-use exposures, is a poorly predictable combination in anyone with existing insulin dysregulation.
- **Cardiovascular vulnerability.** GH excess is associated with sodium and water retention, expanded extracellular fluid and cardiomegaly. Layered on top is the 28-day myocardial degeneration seen with a structurally distinct GHS-R1a agonist in rats [9]. Chronic systemic agonism at this receptor in a subject with underlying cardiac disease is the specific concern.
- **Appetite and adiposity.** Ghrelin-receptor agonists activate hypothalamic appetite circuitry and induce feeding. Ipamorelin has also shown GH-independent stimulation of adiposity and elevated leptin in both GH-deficient and GH-intact mice, meaning part of the body-composition effect operates through GHS-R signalling rather than the GH axis — a class-level orexigenic and adipogenic signal that the compound's GH selectivity does not neutralise.
- **The evidence gaps are documented, not theoretical.** One 114-patient trial of up to seven days of intravenous dosing [10] and one acute single-dose infusion study [11] constitute the entire controlled human record. The dominant real-world route has no published safety or pharmacokinetic characterisation at all, and unregulated research-grade material carries no assurance of identity, purity or sterility.
- **Prohibited in sport at all times** under WADA category S2, with established urine detection methods.

## Where it sits on the map

Ipamorelin is the ghrelin-receptor position on this desk, and it is the only compound here that reaches GH release without touching GHRHR. Against CJC-1295 and sermorelin it is the mechanistic complement rather than the alternative; against MOTS-c it has nothing in common at all beyond appearing in the same product catalogues.

Read by evidence maturity rather than by mechanism, its position changes. It is the only compound on this desk to have completed a randomised controlled trial in patients, and the only one whose trial reported a negative primary endpoint [10]. Both halves of that sentence belong in any honest summary.

---

Precision Peptide Planner charts where four growth-hormone-axis compounds bind and what the studies actually measured — a receptor map drawn from the literature, not a clinic, not a supplier, and not a protocol anyone can follow.